N2-cycloheptyl-N4-[(1-ethyl-2-pyrrolidinyl)methyl]-N6-(4-methylthiophenyl)-1,3,5-triazine-2,4,6-triamine | 502766-54-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N2-cycloheptyl-N4-[(1-ethyl-2-pyrrolidinyl)methyl]-N6-(4-methylthiophenyl)-1,3,5-triazine-2,4,6-triamine
• 英文别名: 2-N-cycloheptyl-6-N-[(1-ethylpyrrolidin-2-yl)methyl]-4-N-(4-methylsulfanylphenyl)-1,3,5-triazine-2,4,6-triamine
• CAS: 502766-54-3
• 化学式: C₂₄H₃₇N₇S
• 分子量: 455.671
• InChiKey: QDZAFZSPDJXANR-UHFFFAOYSA-N

物化性质

• 沸点：
  635.0±61.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Triazine compounds and their analogs, compositions, and methods
  申请人：Timmer T. Richard

  公开号：US20050227983A1

  公开（公告）日：2005-10-13

  The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.

  本发明涉及三嗪化合物及其类似物和衍生物，以及包含这些化合物的方法和组合物。本发明的化合物和组合物可用于治疗由炎症反应引起的病理生理条件，抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应，抑制平滑肌增殖，治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化等。
• Methods and compositions of novel triazine compounds
  申请人：——

  公开号：US20040077648A1

  公开（公告）日：2004-04-22

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及使用化合物治疗由炎症反应引起的病理生理状态的方法和组合物。特别是，本发明涉及抑制或阻断糖基化蛋白在内皮细胞中诱导信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别是，本发明涉及通过调节HSPG（例如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，例如再狭窄和动脉粥样硬化。
• Medical devices employing triazine compounds and compositions thereof
  申请人：Timmer T. Richard

  公开号：US20050113341A1

  公开（公告）日：2005-05-26

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及使用化合物治疗由炎症反应引起的病理生理状态的方法和组合物。具体而言，本发明涉及抑制或阻断糖基化蛋白质诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。具体而言，本发明涉及通过调节HSPGs，如Perlecan，抑制平滑肌细胞增殖的化合物。本发明还涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化。
• US7112587B2
  申请人：——

  公开号：US7112587B2

  公开（公告）日：2006-09-26
• US7132423B2
  申请人：——

  公开号：US7132423B2

  公开（公告）日：2006-11-07